GlassScriptPhysician profile
Victoria Baker Stephens
NPI 1568929156
$1,976.91
in general payments reported to CMS, 2019-2025
26 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $84.59 · 2023: $670 · 2024: $752 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.24 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $221.71 | 2021-2024 | |
| Daiichi Sankyo INC. | $182.61 | 2023-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $166.31 | 2024-2025 | Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $165.80 | 2023-2025 | |
| Stemline Therapeutics INC. | $140.32 | 2023-2024 | Orserdu, Elzonris |
| Novartis Pharmaceuticals Corporation | $127.69 | 2023-2024 | |
| Mirati Therapeutics, INC. | $121.84 | 2023 | Krazati |
| Epizyme, INC. | $121.42 | 2021 | |
| Beigene USA, INC. | $120.43 | 2023-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $100.64 | 2023-2025 | Enhertu, Tagrisso |
| Seagen INC. | $99.95 | 2023 | |
| Karyopharm Therapeutics INC. | $70.55 | 2022 | |
| Lilly USA, LLC | $61.72 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $44.10 | 2024 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $24.24 | 2024 | Padcev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.97 | 2023 | |
| Deciphera Pharmaceuticals INC. | $22.96 | 2024 | Qinlock |
| Recordati_rare_diseases_inc. | $22.76 | 2023 | Panhematin |
| Pharmaessentia USA Corporation | $22.41 | 2025 | Besremi |
| Azurity Pharmaceuticals, INC. | $20.88 | 2025 | Danziten |
| Emd Serono, INC. | $18.26 | 2024 | |
| Abbvie INC. | $17.84 | 2025 | |
| Eisai INC. | $17.10 | 2023 | |
| Array Biopharma INC | $15.35 | 2024 | Braftovi, Mektovi, Tukysa |
| Sobi, INC | $14.04 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.01 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.